Phase 2 Lung Cancer Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who understand what the trial involves and are willing to sign and date a consent form.
- People aged 18 to 80 years old.
- People who have been confirmed through tissue or cell testing to have locally advanced or spreading non-small cell lung cancer (a type of lung cancer), with no prior systemic treatment, and with specific gene changes known as EGFR-sensitive mutations (19del, L858R, or T790M).
- People who have a tumour blocking at least one-third of a major airway (such as the windpipe or a main breathing tube), as assessed by a camera procedure, where that blockage may be treated with a burning/removal procedure — breathing symptoms or a blocked-airway chest infection related to this are also acceptable.
- People with a physical fitness score of 0 to 2 on the ECOG scale, which measures how much a condition affects daily activity (confirm with trial site).
- People whose survival is expected to be at least 12 weeks.
- People whose bone marrow, heart, liver, and kidney function meet the required levels for this trial (confirm specific thresholds with trial site).
- People who have at least one measurable tumour area based on standard imaging measurement rules (RECIST 1.1).
- People who have brain metastases (cancer that has spread to the brain) that are stable may also be considered.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People diagnosed with small cell lung cancer, large cell lung cancer, or neuroendocrine carcinoma as the main tumour type; people whose tumour carries other driver gene mutations are generally also not eligible (confirm with trial site).
- People who have a severely blocked airway causing sudden or life-threatening breathing difficulty, airway compression from outside the airway, large fluid build-up around the lungs, severe coughing, major coughing up of blood, or very poor lung function; also people assessed by the doctor as unable to tolerate treatment or unable to walk.
- People who have already had systemic treatment for their locally advanced or metastatic disease.
- People with serious blood clotting problems that cannot be corrected, a very low platelet count, or severe clotting dysfunction.
- People who currently have brain metastases that are causing symptoms.
- People with a known serious allergic reaction (grade 3 or higher) to anti-PD-1 antibody medicines or similar drugs.
- People with an ongoing or active infection, including hepatitis B, hepatitis C, or HIV.
- People who currently have another cancer, other than certain minor skin cancers or early-stage cervical changes — though people who had a previous cancer but have shown no signs of disease for 3 or more years may still be considered.
- People who are pregnant or breastfeeding.
- People who the trial doctor assesses as unsuitable for the study for any other reason.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +8613873123436
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Objective Response Rate of Airway Tumor
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.